Cargando…

Cardiovascular Disease and Stroke in Immune TTP–Challenges and Opportunities

Advances in the management of immune thrombotic thrombocytopenic purpura (iTTP) have dramatically improved outcomes of acute TTP episodes, and TTP is now treated as a chronic, relapsing disorder. It is now recognized that iTTP survivors are at high risk for vascular disease, with stroke and myocardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sukumar, Senthil, Mazepa, Marshall A., Chaturvedi, Shruti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531888/ https://www.ncbi.nlm.nih.gov/pubmed/37762903 http://dx.doi.org/10.3390/jcm12185961

Ejemplares similares

Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
por: Sukumar, Senthil, et al.
Publicado: (2022)

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura
por: Shah, Hridaya, et al.
Publicado: (2022)

Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions
por: Lemiale, Virginie, et al.
Publicado: (2021)

P1612: CALPROTECTIN LEVELS ARE ELEVATED IN CONGENITAL TTP AND IMMUNE TTP AT ADAMTS13 RELAPSE
por: Subhan, Maryam, et al.
Publicado: (2023)

TTP: From empiricism for an enigmatic disease to targeted molecular therapies
por: Graça, Nuno A. G., et al.
Publicado: (2022)

Tacrolimus associated thrombotic thrombocytopenic purpura (TTP) and stroke in the young
por: Maramattom, Boby Varkey, et al.
Publicado: (2015)

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase
por: Westwood, John Paul, et al.
Publicado: (2022)

Gut microbiota and cardiovascular disease: opportunities and challenges
por: Kazemian, Negin, et al.
Publicado: (2020)

ADAMTS13, TTP and Beyond
por: Zheng, X Long
Publicado: (2012)

Analysis of ROQUIN, Tristetraprolin (TTP), and BDNF/miR-16/TTP regulatory axis in late onset Alzheimer’s disease
por: Asadi, Mohammad Reza, et al.
Publicado: (2022)

Tenecteplase in Ischemic Stroke: Challenge and Opportunity
por: Li, Guangshuo, et al.
Publicado: (2022)

Adiponectin and metabolic cardiovascular diseases: Therapeutic opportunities and challenges
por: Lei, Xiaotian, et al.
Publicado: (2022)

Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)
por: Butt, Ayesha, et al.
Publicado: (2023)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

P1598: UTILITY OF ‘OPEN/CLOSED’ ADAMTS13 IN MONITORING IMMUNE TTP
por: Prasannan, Nithya, et al.
Publicado: (2023)

TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease
por: Chang, Jae C.
Publicado: (2018)

Successful Use of Bortezomib in an Adolescent with Refractory TTP
por: Wali, Junaid Ahmad, et al.
Publicado: (2023)

Multilevel regulation of HIF-1 signaling by TTP
por: Fähling, Michael, et al.
Publicado: (2012)

Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)
por: King, Jeanelle, et al.
Publicado: (2017)

From TTP to Glomerulonephritis: A Lifetime of Lupus
por: Kharouf, Fadi, et al.
Publicado: (2021)

PB2322: TTP AFTER COVID 19
por: Gagloeva, D., et al.
Publicado: (2022)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
por: Yenerel, Mustafa N.
Publicado: (2014)

Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients
por: Fodil, Sofiane, et al.
Publicado: (2022)

Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
por: Mahmud, Shabnur, et al.
Publicado: (2022)

Challenges and Opportunities in the Evaluation of Nutraceuticals in Cardiovascular Diseases
por: Sharma, Abhinav, et al.
Publicado: (2021)

Microangiopathic Anemia of Acute Brucellosis – is it a True TTP?
por: Kuperman, Amir A, et al.
Publicado: (2010)

Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities
por: Yang, Pingping, et al.
Publicado: (2023)

Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020)

Two novel proteins, TtpB2 and TtpD2, are essential for iron transport in the TonB2 system of Vibrio vulnificus
por: Barnes, Adel D., et al.
Publicado: (2019)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

A case of congenital TTP presenting with microganiopathy in adulthood
por: Gallivan, Chris D, et al.
Publicado: (2014)

Myelodysplastic Syndrome Clinically Presenting with the “Classic TTP Pentad”
por: Moscoso Martínez, Santiago Fabián, et al.
Publicado: (2017)

COVID-19-ASSOCIATED THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP)
por: JAIN, HANISH, et al.
Publicado: (2022)

H(2)S-based therapies for ischaemic stroke: opportunities and challenges
por: Jia, Jia, et al.
Publicado: (2019)

Molecular Analysis of TTP, a Key Regulator of TNF Activity
por: Johnson, Barbra A., et al.
Publicado: (2001)

LATE-ONSET IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AFTER ASYMPTOMATIC COVID-19 INFECTION
por: SALUJA, PRACHI, et al.
Publicado: (2022)

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
por: Packard, Chris, et al.
Publicado: (2021)

Initial ‘TTP Map-Defect’ of Computed Tomography Perfusion as a Predictor of Hemorrhagic Transformation of Acute Ischemic Stroke
por: Shinoyama, Mizuya, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s01tdh81lpn4pjm41s6svahfu8